Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

NICE positive recommendation supports use of BAVENCIO®? (avelumab) for treatment of adults in England, Wales and Northern Ireland with metastatic Merkel Cell Carcinoma, a rare skin cancer

Posted on: 01 Mar 18
  • Welcome news for patients in England, Wales and Northern Ireland as avelumab is recommended for routine NHS use in previously treated metastatic Merkel Cell Carcinoma (mMCC) patients and for use in England within the Cancer Drugs Fund (CDF) for those with previously untreated mMCC


  • The recommendation means patients with this rare, aggressive form of skin cancer will now be able to access NHS treatment with avelumab which, in September 2017, became the first and only targeted systemic treatment to be licensed for mMCC.[i]



Feltham (Merck) & Walton Oaks (Pfizer), 1st March 2018 –The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) that recommends avelumab for treating adults with metastatic Merkel Cell Carcinoma (mMCC).[ii] Avelumab is recommended for routine NHS use in England, Wales and Northern Ireland for treating metastatic mMCC in adults, only if they have had one or more lines of chemotherapy for metastatic disease. Avelumab is recommended for use in England within the Cancer Drugs Fund (CDF) for treating mMCC in adults only if: they have not had chemotherapy for metastatic disease and the conditions in the managed access scheme are followed.


Access to avelumab for previously untreated mMCC through the CDF applies in England. Patients across Wales will also be able to access the medicine through the New Treatment Fund, which funds all treatments with a positive recommendation from NICE (and the All Wales Medicines Strategy Group), including those in the CDF with draft recommendations. Health boards and Velindre NHS Trust have 60 days to implement a recommendation following the publication of a FAD and once a Commercial Access Agreement (CAA) has been signed. In Scotland, the outcome of an assessment by the Scottish Medicines Consortium is awaited, with a decision expected in the first half of 2018.


The NICE recommendation is not intended to affect treatment with avelumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.


Avelumab’s inclusion in the CDF for a time-limited period, while the first-line mMCC trial data are maturing, is NICE’s preferred option, after which the clinical and cost-effectiveness of avelumab in the first-line setting will be re-evaluated by NICE. The decision by NICE to include avelumab for first-line use in mMCC in the CDF recognises the clinical benefit and patients’ unmet need in this setting.


“Merck and Pfizer are really pleased with today’s decision by NICE, which will result in patients in England, Wales and Northern Ireland being able to access the first targeted systemic treatment option licensed in the UK for metastatic Merkel Cell Carcinoma,” commented Belinda Byrne, Medical Director at Merck. “We have worked closely with NICE and the CDF to ensure all mMCC patients can get access to avelumab as early as possible in their treatment.”


Catherine Bouvier, Chief Executive of NET Patient Foundation, UK, said: “It’s fantastic news that NICE can recommend a treatment such as avelumab for patients with metastatic Merkel Cell Carcinoma. Patients with such rare cancers often don’t have access to funded treatments. This is a great outcome for patients and their families.”


Patients with mMCC have a very poor prognosis, with fewer than half of patients surviving more than one year and fewer than 20% surviving beyond five years.[iii] There are thought to be approximately 70 new cases of mMCC in England every year, although the accuracy of this figure is difficult to determine due to the rarity of Merkel Cell Carcinoma.[iv]  Data show that the incidence of MCC is rising,[v],[vi] possibly due to an ageing population or increased UV exposure.6 MCC exhibits aggressive clinical features, including frequent lymph node involvement and early metastases.[vii],[viii],[ix]


While earlier-stage MCC can be generally managed with surgery and radiotherapy, treatment options for mMCC are severely limited.[x],[xi] Until the UK launch of avelumab in November 2017, the only licensed treatment option for mMCC was cytotoxic chemotherapy, which has limited efficacy and is not generally well-tolerated. The preferred standard of care for mMCC, according to the NCCN guidelines, is clinical trials, but other immuno-oncology drugs are also stated as options.11


The recommendation in the FAD forms the basis of NICE’s final guidance (Technology Appraisal Guidance, TAG), anticipated over the coming weeks.


Avelumab received marketing authorisation on 20th September 2017 in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland, and was subsequently launched in the UK in November 2017.

Editor's Details

Mike Wood

Last updated on: 01/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.